{"contentid": 488756, "importid": NaN, "name": "In multiple myeloma, more competition is on the way", "introduction": "The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency\u00e2\u0080\u0099s Priority Review scheme, with a decision expected by November 29.", "content": "<p>The US Food and Drug Administration will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency&rsquo;s Priority Review scheme, with a decision expected by November 29.</p>\n<p>The BCMA-directed CAR-T cell therapy, developed by Legend Biotech (Nasdaq: LEGN), is being investigated as a treatment for multiple myeloma as a later line option.</p>\n<p>Backed by data from the Phase Ib/II CARTITUDE-1 study, the therapy has already been submitted for marketing authorization with the European Medicines Agency (EMA).</p>\n<p>Updated longer-term follow up data will be featured at the upcoming American Society of Clinical Oncology (ASCO) annual meeting.</p>\n<h2>BCMA competition</h2>\n<p>Legend, a spin-out of Hong Kong-listed GenScript Biotech, has been working with US healthcare giant Johnson &amp; Johnson (NYSE: JNJ) on the development of cilta-cel since December 2017.</p>\n<p>The companies have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize the treatment, with J&amp;J providing an upfront payment of $350 million as part of the deal.</p>\n<p>Multiple firms are now involved in the development of BCMA-targeted treatments, which is hotly anticipated as an area of high therapeutic potential.</p>\n<p>Leading the pack is UK drugmaker GlaxoSmithKline (LSE: GSK), which was the first to market this kind of treatment, with US approval in December 2020 for Blenrep (belantamab mafodotin-blmf), a first-in-class antibody-drug conjugate (ADC) targeting BCMA.</p>\n<p>In March 2021, Bristol-Myers Squibb (NYSE: BMY) and bluebird bio (Nasdaq: BLUE) won US approval for Abecma (idecabtagene vicleucel) (ide-cel), another BCMA-targeting therapy which - like Legend and J&amp;J&rsquo;s option - uses CAR-T cell technology.</p>\n<p>According to research from industry analyst Facts and Factors, global revenues from such therapies could grow by around 20% annually to reach $16 billion by the end of 2026.</p>", "date": "2021-05-27 10:23:00", "meta_title": NaN, "meta_keywords": "therapy, multiple, cilta-cel, myeloma, competition, submission, cancer, November, expected, decision, scheme, Review, Priority, autoleucel, ciltacabtagene", "meta_description": "The US regulator will consider a submission for novel cancer therapy ciltacabtagene autoleucel (cilta-cel) under the agency\u00e2\u0080\u0099s Priority Review scheme, with a dec", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-27 10:23:07", "updated": "2021-05-27 10:43:09", "access": NaN, "url": "https://www.thepharmaletter.com/article/in-multiple-myeloma-more-competition-is-on-the-way", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "biotech_lab_big.jpg", "image2id": "biotech_lab_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "ASCO, Drug Trial, Focus On, Regulation, Research, US FDA", "geography_tag": "Hong Kong, UK, USA", "company_tag": "Amgen, bluebird bio, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Legend Biotech", "drug_tag": "Abecma, Blenrep, ciltacabtagene autoleucel", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-27 10:23:00"}